Advertisement

Most Popular on Medindia

P
M

Chemotherapy After Surgery Increased Survival Rates in Women With Breast Cancer

by Bidita Debnath on  December 09, 2012 at 7:58 PM Research News   - G J E 4
In women with regional recurrence of breast cancer, chemotherapy or adjuvant chemotherapy, led to higher rates of disease-free and overall survival.

This is according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 4-8.
 Chemotherapy After Surgery Increased Survival Rates in Women With Breast Cancer

Patients with isolated local and/or regional recurrence of their breast cancers are at high risk for developing metastases in other areas of the body. Some physicians administer chemotherapy to these patients after their recurrent tumors have been completely removed by surgery, but the efficacy of this treatment had not been studied until now.

"This is the first randomized controlled study that shows that adjuvant chemotherapy works in these patients," said Stefan Aebi, M.D., head of the division of medical oncology at Luzerner Kantonsspital in Luzern, Switzerland.

He and his colleagues from the Breast International Group, the National Surgical Adjuvant Breast and Bowel Project and the International Breast Cancer Study Group evaluated 162 patients with isolated local and regional recurrence; 85 received adjuvant chemotherapy and 77 did not.

Five-year disease-free survival rates were 69 percent for women who received adjuvant chemotherapy and 57 percent for those who did not. The overall survival rate was 88 percent for women who received chemotherapy compared with 76 percent for those who did not.

Women with estrogen receptor (ER)-negative breast cancer demonstrated the greatest benefit, with a five-year disease-free survival rate of 67 percent among those who received chemotherapy versus 35 percent among those who did not. In addition, within this group, overall survival rates were 79 percent among those who received chemotherapy and 69 percent among those who did not.

For patients with ER-positive disease, five-year disease-free survival was 70 percent for those who received chemotherapy versus 69 percent for those who did not. Overall survival was 94 percent for those patients with ER-positive disease who received chemotherapy versus 80 percent among those who did not.

Aebi recommended that physicians prescribe adjuvant chemotherapy for patients with isolated local and regional recurrence of breast cancer, especially if the recurrence is ER-negative and therefore not sensitive to endocrine therapy.

This research was funded by the National Cancer Institute, the Swiss Cancer League and other national cancer research agencies.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

Ask an Expert

C
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Ask an Expert

Ask an Expert+
s
Potential Strategy for Designing Therapeutics for...
 Potential Strategy for Designing Therapeutics for Neurodegenerative Disease
S  Obesity Reversed in Mice
Obesity Reversed in Mice